195 related articles for article (PubMed ID: 16478752)
1. The impact of experimental design on assessing mechanism-based inactivation of CYP2D6 by MDMA (Ecstasy).
Van LM; Heydari A; Yang J; Hargreaves J; Rowland-Yeo K; Lennard MS; Tucker GT; Rostami-Hodjegan A
J Psychopharmacol; 2006 Nov; 20(6):834-41. PubMed ID: 16478752
[TBL] [Abstract][Full Text] [Related]
2. Inactivation of CYP2D6 by methylenedioxymethamphetamine in different recombinant expression systems.
Van LM; Hargreaves JA; Lennard MS; Tucker GT; Rostami-Hodjegan A
Eur J Pharm Sci; 2007 Sep; 32(1):8-16. PubMed ID: 17574396
[TBL] [Abstract][Full Text] [Related]
3. Kinetics of the time-dependent inactivation of CYP2D6 in cryopreserved human hepatocytes by methylenedioxymethamphetamine (MDMA).
Van LM; Swales J; Hammond C; Wilson C; Hargreaves JA; Rostami-Hodjegan A
Eur J Pharm Sci; 2007 May; 31(1):53-61. PubMed ID: 17387004
[TBL] [Abstract][Full Text] [Related]
4. The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans.
O'Mathúna B; Farré M; Rostami-Hodjegan A; Yang J; Cuyàs E; Torrens M; Pardo R; Abanades S; Maluf S; Tucker GT; de la Torre R
J Clin Psychopharmacol; 2008 Oct; 28(5):523-9. PubMed ID: 18794647
[TBL] [Abstract][Full Text] [Related]
5. Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine.
Heydari A; Yeo KR; Lennard MS; Ellis SW; Tucker GT; Rostami-Hodjegan A
Drug Metab Dispos; 2004 Nov; 32(11):1213-7. PubMed ID: 15328252
[TBL] [Abstract][Full Text] [Related]
6. Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans.
Yubero-Lahoz S; Pardo R; Farré M; O'Mahony B; Torrens M; Mustata C; Pérez-Mañá C; Carbó ML; de la Torre R
Clin Pharmacokinet; 2011 May; 50(5):319-29. PubMed ID: 21456632
[TBL] [Abstract][Full Text] [Related]
7. Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA.
Yang J; Jamei M; Heydari A; Yeo KR; de la Torre R; Farré M; Tucker GT; Rostami-Hodjegan A
J Psychopharmacol; 2006 Nov; 20(6):842-9. PubMed ID: 16714321
[TBL] [Abstract][Full Text] [Related]
8. Potent inhibition of cytochrome P-450 2D6-mediated dextromethorphan O-demethylation by terbinafine.
Abdel-Rahman SM; Marcucci K; Boge T; Gotschall RR; Kearns GL; Leeder JS
Drug Metab Dispos; 1999 Jul; 27(7):770-5. PubMed ID: 10383919
[TBL] [Abstract][Full Text] [Related]
9. Effect of sodium ozagrel on the activity of rat CYP2D6.
Wu H; Yu W; Huang L; Wang J; Tang X; Yang W; Liu Y; Yu H; Zhu D
Eur J Pharmacol; 2007 Nov; 573(1-3):55-9. PubMed ID: 17651725
[TBL] [Abstract][Full Text] [Related]
10. Mechanism-based inactivation of CYP2D6 by 5-fluoro-2-[4-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-piperazinyl]pyrimidine.
Palamanda JR; Casciano CN; Norton LA; Clement RP; Favreau LV; Lin C; Nomeir AA
Drug Metab Dispos; 2001 Jun; 29(6):863-7. PubMed ID: 11353755
[TBL] [Abstract][Full Text] [Related]
11. Metabolism of dextrorphan by CYP2D6 in different recombinantly expressed systems and its implications for the in vitro assessment of dextromethorphan metabolism.
Van LM; Sarda S; Hargreaves JA; Rostami-Hodjegan A
J Pharm Sci; 2009 Feb; 98(2):763-71. PubMed ID: 18543297
[TBL] [Abstract][Full Text] [Related]
12. Interaction of terfenadine and its primary metabolites with cytochrome P450 2D6.
Jones BC; Hyland R; Ackland M; Tyman CA; Smith DA
Drug Metab Dispos; 1998 Sep; 26(9):875-82. PubMed ID: 9733666
[TBL] [Abstract][Full Text] [Related]
13. The in vitro interaction of dexmedetomidine with human liver microsomal cytochrome P4502D6 (CYP2D6).
Rodrigues AD; Roberts EM
Drug Metab Dispos; 1997 May; 25(5):651-5. PubMed ID: 9152607
[TBL] [Abstract][Full Text] [Related]
14. The in vitro inhibitory potential of trade herbal products on human CYP2D6-mediated metabolism and the influence of ethanol.
Hellum BH; Nilsen OG
Basic Clin Pharmacol Toxicol; 2007 Nov; 101(5):350-8. PubMed ID: 17910620
[TBL] [Abstract][Full Text] [Related]
15. Mechanism-based inactivation of cytochrome P450 2D6 by 1-[(2-ethyl-4-methyl-1H-imidazol-5-yl)methyl]- 4-[4-(trifluoromethyl)-2-pyridinyl]piperazine: kinetic characterization and evidence for apoprotein adduction.
Hutzler JM; Steenwyk RC; Smith EB; Walker GS; Wienkers LC
Chem Res Toxicol; 2004 Feb; 17(2):174-84. PubMed ID: 14967005
[TBL] [Abstract][Full Text] [Related]
16. Mechanism-based inhibition of human liver microsomal cytochrome P450 2D6 (CYP2D6) by alkamides of Piper nigrum.
Subehan ; Usia T; Kadota S; Tezuka Y
Planta Med; 2006 May; 72(6):527-32. PubMed ID: 16808005
[TBL] [Abstract][Full Text] [Related]
17. Kinetic values for mechanism-based enzyme inhibition: assessing the bias introduced by the conventional experimental protocol.
Yang J; Jamei M; Yeo KR; Tucker GT; Rostami-Hodjegan A
Eur J Pharm Sci; 2005 Nov; 26(3-4):334-40. PubMed ID: 16137870
[TBL] [Abstract][Full Text] [Related]
18. Binding of bufuralol, dextromethorphan, and 3,4-methylenedioxymethylamphetamine to wild-type and F120A mutant cytochrome P450 2D6 studied by resonance Raman spectroscopy.
Bonifacio A; Keizers PH; Commandeur JN; Vermeulen NP; Robert B; Gooijer C; van der Zwan G
Biochem Biophys Res Commun; 2006 May; 343(3):772-9. PubMed ID: 16563352
[TBL] [Abstract][Full Text] [Related]
19. Characterization of dextromethorphan O- and N-demethylation catalyzed by highly purified recombinant human CYP2D6.
Yu A; Dong H; Lang D; Haining RL
Drug Metab Dispos; 2001 Nov; 29(11):1362-5. PubMed ID: 11602510
[TBL] [Abstract][Full Text] [Related]
20. In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude.
Venkatakrishnan K; Obach RS
Drug Metab Dispos; 2005 Jun; 33(6):845-52. PubMed ID: 15788540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
